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Abstract
Background: Hemipelvectomy is a major orthopedic surgical procedure indicated in specific situations. Although
many studies discuss surgical techniques for hemipelvectomy, few studies have presented survival data, especially
in underdeveloped countries. Additionally, there is limited information on anesthesia for orthopedic oncologic
surgeries. The primary aim of this study was to determine the survival rate after hemipelvectomy, and the secondary
aims were to evaluate anesthesia and perioperative care associated with hemipelvectomy and determine the influence
of the surgical technique (external hemipelvectomy [amputation] or internal hemipelvectomy [limb sparing surgery])
on anesthesia and perioperative care in Brazil.
Methods: This retrospective case series collected data from 35 adult patients who underwent hemipelvectomy
between 2000 and 2013. Survival rates after surgery were determined, and group comparisons were performed using
the Kaplan–Meier method and the log-rank test. Mantel–Cox test and multiple linear regression analysis with stepwise
forward selection were performed for univariate and multivariate analyses, respectively.
Results: Mean survival time was 32.8 ± 4.6 months and 5-year survival rate was 27 %. Of the 35 patients, 23 patients
(65.7 %) underwent external hemipelvectomy and 12 patients (34.3 %) underwent internal hemipelvectomy. The
survival rate was significantly higher in patients with bone tumors than in those with soft tissue sarcomas (P = 0.024).
The 5-year cumulative probability of survival was significantly lower in patients who underwent external
hemipelvectomy than in those who underwent internal hemipelvectomy (P = 0.043). In the univariate and
multivariate analyses, only advanced disease stage (3 and 4) was identified as a significant independent
predictor of reduced survival (P = 0.0003). Balanced general anesthesia combined with epidural block was
the most frequent anesthesia technique. Median intraoperative crystalloid volume and red blood cell transfusions
were 3500 mL and 2 units, respectively.
Conclusions: Overall mean survival time after hemipelvectomy was 32.8 months. Advanced disease stage might be
independently associated with reduced survival. Smaller amounts of fluids and transfusions were administered and
time to discharge was shorter. Acute and chronic pain as well as wound complications are still important challenges
in hemipelvectomy.
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Background
Hemipelvectomy is a major orthopedic surgical proced-
ure indicated in specific situations and regularly per-
formed in highly complex tertiary centers [1, 2]. Primary
bone and soft tissue pelvic sarcomas are the main indi-
cations for hemipelvectomy [3], which has been used in
specific critical pelvic trauma patients [4]. Since it was
first performed by Billroth in 1891 [5], perioperative care
has been a challenge for all health-care providers in-
volved in this aggressive procedure.
Hemipelvectomy involves the following two different
approaches: external approach (with limb amputation)
and internal approach (with limb preservation) [5]. In
the last few decades, the use of external hemipelvectomy
for the treatment of pelvic cancer has declined, and new
surgical techniques and efforts for resection with limb
preservation (internal hemipelvectomy) and reconstruc-
tion have been introduced [6–8].
Survival after hemipelvectomy might be related to sev-
eral different factors, such as tumor histopathology and
size, disease stage, patient physical status, and resection
type. In patients with soft tissue tumors, the 5-year sur-
vival rate might be as low as 10 %. Large tumors and
bone and vascular involvement might be indicators of
poor survival [8]. For bone tumor resection, the 5-year
survival rate can be as high as 100 %, depending on the
resection type [9]. A large previous series reported a sur-
vival rate of 50 % after hemipelvectomy [10].
With regard to hemipelvectomy, anesthesia and peri-
operative care may be considered challenging because of
extensive tissue trauma related to the surgery, the use of
preoperative adjuvant chemotherapy and radiotherapy, sig-
nificant blood and fluid loss, bleeding disorders, and intense
postoperative pain [11]. In most cases, major neurovascular
dissection, large bone resection and reconstruction, and
skin flap rotation are needed [2]. Although many studies
have discussed surgical techniques for hemipelvectomy, few
studies [6, 7, 12] have presented survival data, especially in
underdeveloped countries [9]. Additionally, there is limited
information on anesthesia for orthopedic oncologic surger-
ies [2]. We found only one paper that presented anesthetic
and perioperative data specifically for hemipelvectomy. The
paper was published in 2007 [11].
The primary aim of this study was to determine the sur-
vival rate after hemipelvectomy, and the secondary aims
were to evaluate anesthesia and perioperative care associ-
ated with hemipelvectomy and determine the influence of
the surgical technique (external hemipelvectomy [amputa-
tion] or internal hemipelvectomy [limb sparing surgery])
on anesthesia and perioperative care in Brazil.
Methods
This retrospective case series collected data from the
medical records and from the Department of Pathology
database of all patients who underwent hemipelvectomy
at Instituto Nacional de Câncer, Brazil, between 2000
and 2013. Patients aged under 18 years were excluded
from the search. The study was approved by the
Research Ethics Committee of Instituto Nacional de
Câncer José Alencar Gomes da Silva (reference number
82751/CAAE 05859312.9.0000.5274).
The variables of interest were associated disorders, age,
sex, weight, American Society of Anesthesiologists Phys-
ical Status classification, tobacco use, preoperative chemo-
therapy and radiotherapy, tumor size and histology,
disease stage, type of procedure, operation time, type of
anesthesia, neuroaxial opioid use, amount of crystalloids
and colloids infused, perioperative transfusion, and extu-
bation. In addition, postoperative variables (acute and
chronic pain, surgical wound, and clinical complications)
and hospital length of stay were studied.
As no specific guidelines were described in the database
or medical charts, the choice of anesthesia technique as
well as transfusion triggers was based on individual criteria
of personal experience and subjective team evaluation.
Pain was assessed using the visual analog scale (VAS)
and was considered severe if the VAS score was >7 and
chronic if it persisted for over 12 weeks. Surgical wound
complications included infection, fistula, and dehiscence.
Information regarding follow-up and time to death was
retrieved from the Department of Cancer Information at
our institution. Patients who showed up in the last doctor
appointment were considered alive. All deceased patients
were registered in the database of the institution.
External hemipelvectomy was indicated in cases where
adequate surgical margin could not be obtained with
preservation of a viable and functioning limb. Also, it
was indicated in large tumors with vascular involvement
and ulcerated and great pelvic invasion. Bone recon-
struction was not performed after internal hemipelvect-
omy as it is not routine in this center.
Pelvic resection in internal hemipelvectomy was classi-
fied into the following: iliac (T1), acetabular (T2), pubis
or ischium (T3), and sacral (T4) [12]. Combinations of
procedures were also performed in association with high
femoral resection and/or sacral extension.
Disease staging was performed retrospectively by an
orthopedic oncologic surgeon following the American
Joint Committee on Cancer (AJCC) [13] for soft tissue
sarcomas and the Union for International Cancer Con-
trol (UICC) for cases involving the bone.
Statistical analysis
Median, mean, standard deviation, and range were used
to summarize numerical data, and frequency (n) and
percentage (%) were used for categorical data. The asso-
ciations between variables were analyzed using the
Mann–Whitney U test for numerical data and the χ2 test
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or Fisher’s exact text for categorical data, as the
Shapiro–Wilk normality test was rejected.
The survival rate after surgery was calculated using
the Kaplan–Meier method, and the log-rank test was
used for comparisons. Survival curves compared groups
dichotomized by age (under 50 vs. 50 years or more),
tumors (bone vs. soft tissue), and type of surgery
(internal vs. external).
To identify factors that could independently influence
survival, univariate analysis was performed with Mantel–
Cox regression for each variable. The candidate variables
included sex, age, preoperative radiotherapy and chemo-
therapy, transfusion, intraoperative fluid volume, and
disease stage. Multivariate analysis was performed using
multiple linear regression with forward selection.
All analyses were performed using SAS® System 6.11
(SAS Institute, Inc., Cary, NC). A P value <0.05 was con-
sidered significant.
Results
Thirty-five cases were selected for analysis after database
searches.
The preoperative data are presented in Table 1. Ambu-
latory anesthesia preoperative evaluation was performed
2–3 weeks before hemipelvectomy in 12 patients, and 23
patients were visited by an anesthesiologist before sur-
gery after hospital admission. Thirty-three procedures
were elective and 2 were considered emergency owing to
tumor bleeding.
Twelve patients presented soft tissue tumors and 23
had primary bone tumors. Classic chondrosarcoma was
the most frequent case (15 cases, 1 recurrence). Two
chondrosarcomas were classified as mesenchymal (bone,
1; soft tissue [extra-skeletal], 1). Among the osteosar-
comas, 1 was fibroblastic, 1 was chondroblastic, 1 was
small cell, and 3 were classic.
The other sarcomas included 1 clear cell, 2 pleo-
morphic, 1 high-grade, 1 undifferentiated, and 1 fibro-
sarcoma. Of these 6 cases, 4 were recurrent. Malignant
fibrous histiocytoma was pleomorphic in 2 cases (1 re-
current) and myxoid in 1 case. There were 2 cases of
synovial cell sarcoma and 1 giant cell tumor.
Of the 12 cases of soft tissue tumors, 5 were stage 3, 2
were stage 4, and 5 were local recurrences. Of the 23
bone tumors, 13 were stage 2b, 8 were stage 1b, 1 was
stage 3, and 1 was local recurrence. Among the 12 pa-
tients with soft tissue tumors, 9 (75 %) had tumors
>10 cm; and among the patients with bone tumors, 19
(82.6 %) had tumors >8 cm.
The surgical procedures are presented in Table 2.
The 5-year survival rates after surgery are presented in
Fig. 1.
The mean survival time was 32.8 ± 4.6 months, and
the survival rate after 5 years was 27 %. The survival rate
was higher among patients with bone tumors than
among those with soft tissue sarcomas (P = 0.024). Add-
itionally, the cumulative probability of survival at 5 years
was lower among patients who underwent external
hemipelvectomy than among those who underwent in-
ternal hemipelvectomy (P = 0.043). Internal hemipelvect-
omy patients presented a survival rate of 57 % in 5 years
while external hemipelvectomy patients had only 11 %
in the same time interval. However, the survival rate dif-
ference was not statistically significant between patients
aged <50 at the time of the procedure and those aged
≥50 at the time of the procedure (P = 0.083).
In the univariate analysis, only advanced disease stage
(3 and 4) was found to be a significant independent fac-
tor for reduced survival among the variables tested (P =
0.0003, hazard ratio = 6.65, 95 % CI = 2.36–18.7).
Table 1 Preoperative data
Variable Value
Age, years (median and range) 40 (18–82)
Weight, kg (mean and range) 69.1 (43–106)
Male/female (n) 24:11
Preoperative radiotherapy (%) 28.6





Tobacco use (n) 15
Arterial hypertension (n) 9
Diabetes (n) 2
Coronary disease (n) 1
Asthma (n) 1
Chronic renal failure (n) 1
Gastroesophageal reflux disease (n) 1
Pulmonary metastasis (n) 4
Depression (n) 2
ASA American Society of Anesthesiologists Physical Status Classification
Table 2 Surgical procedures
Type N
Internal type I 5
Internal type I with sacral extension 1
Internal type II 2
Internal type III 1
Internal types II and III 1
Internal types I, II, and III with high femoral resection 2
External 23
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Additionally, in the multivariate analysis, only advanced
disease stage (3 and 4) was found to be an independent
risk factor for reduced survival.
Data on perioperative management are presented in
Table 3. The median volume of crystalloid infusion was
3500 mL, and 500-mL multiples were used for colloid
administration quantification. Twenty patients received
red blood cell (RBC) concentrates intraoperatively and 4
patients received other blood products in the operating
room (OR). Thirty-three patients underwent tracheal
extubation in the OR. In the perioperative period, a high
number of patients presented at least one episode of se-
vere hemodynamic instability (23 patients, 65.7 %). All
these patients received fluid resuscitation, and vasopres-
sors (infusion, boluses, or both) were required in 12 of
these patients (52.17 %). Six patients presented persist-
ent bleeding disorders with associated abnormal coagu-
lation tests.
Postoperative data are presented in Table 4. Severe and
acute pain after the procedure was noticed in 31.4 % of the
cases and 40 % of the patients developed chronic pain.
Postoperative transfusion was performed in 17 patients.
With regard to postoperative complications, 1 patient de-
veloped acute renal failure, 2 had neurological disorders, 1
had arrhythmia, and 9 developed surgical wound complica-
tions. Median hospital stay after surgery was 6 days.
Comparisons of perioperative data between external
hemipelvectomy and internal hemipelvectomy (without
reconstruction) are presented in Table 5. There were no
significant differences in perioperative data between exter-
nal hemipelvectomy and internal hemipelvectomy (with-
out reconstruction), including time to hospital discharge.
We compared surgical wound complications and the
incidence of chronic pain between external hemipelvect-
omy and internal hemipelvectomy (without reconstruc-
tion) and found no significant differences (P = 0.095 and
P = 0.17, respectively). However, external hemipelvect-
omy was responsible for 8 of the 9 cases of surgical
wound complications. The number of patients with in-
traoperative hemodynamic instability was higher among
patients who underwent external hemipelvectomy than
among patients who underwent internal hemipelvect-
omy (P = 0.003).
Discussion
In this study, mean survival time was 32.8 ± 4.6 months.
In a previous study, Penna et al. [9] demonstrated a
mean survival time of 43 ± 17 months. This difference
could be explained by the fact that a large number of pa-
tients had an advanced disease stage at the time of sur-
gery in this study.
a b
c d
Fig. 1 Survival rate after surgery (n = 29). a Overall survival rate. b Survival rate of patients with bone tumors and those with soft tissue tumors.
c Survival rate of patients aged <50 and those aged ≥50. d Survival rate of patients who underwent internal hemipelvectomy and those who
underwent external hemipelvectomy
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We found that the chance of survival was higher with
internal hemipelvectomy than with external hemipel-
vectomy. This is consistent with the findings of a previ-
ous study [9]. Therefore, if possible, limb preservation
surgery is the first choice when hemipelvectomy is con-
sidered a possible approach. The fact that external hemi-
pelvectomy is currently performed in specific situations
of more advanced disease such as failed neoadjuvant
therapy, severe deep infection, sciatic nerve and femoral
vessel infiltration, local tumor recurrence, improvement
of the resection margin, and as a life-saving or palliative
procedure could possibly explain the higher chances of
survival in the internal hemipelvectomy group [2].
Although we did not notice any significant statistical
difference in survival when patient age (>50 or ≥50) was
considered (P = 0.083), Mankin et al. [10] demonstrated
a higher survival rate after hemipelvectomy in patients
aged <50 than in those aged ≥50. Sample size may have
contributed to this difference.
Among the variables selected, only advanced disease stage
was a significant predictor of reduced survival in both uni-
variate and multivariate analysis (P = 0.001), and this finding
is consistent with the results of a previous study [10].
All patients with soft tissue tumors died at 60 months
after the surgery in this study. However, Appfelstaedt et
al. [8] reported a 10 % survival rate at 5 years for cura-
tive surgery and 14 % for palliation. On evaluating the
data of patients with soft tissue tumors, we found that
almost all the patients had an advanced disease stage
(grade 3 or 4), and this might explain the reduced
survival.
In the present series, 65.7 % of the procedures were
external hemipelvectomy, although limb savage surgeries
have been reported to be possible in most cases owing
to medical advances [14]. Previous studies [9–12] have
reported the predominance of internal hemipelvectomy
in the treatment of pelvic cancer. This difference may be
explained by the large tumor sizes in this study, and it
reflects the high number of patients at an advanced dis-
ease stage assisted at Instituto Nacional de Câncer José
Alencar Gomes da Silva.
Intraoperatively, a median of 2 units (range, 1–6 units)
of RBCs were administered. Hemipelvectomy has been
shown to be associated with massive bleeding and sig-
nificant blood and fluid loss [15]. A previous study re-
ported the requirement of massive transfusions [1], and
another reported that a median of 7 units (range, 0–
44 units) of RBCs were required intraoperatively [11].
Moreover, intraoperatively, a median crystalloid volume
of 3500 mL (range, 1000–8500 mL) was infused, and the
volume administered was lower in this series than in the
study by Molnar et al. [11] (median, 8500 mL; range,
1000–42,000 mL). Additionally, the operation time was
shorter than in the study by Molnar et al. [11] (200 vs.
300 min). These differences might be explained by the
fact that none of the patients who underwent internal
hemipelvectomy had bone reconstruction in this study,
while 19 of 49 patients underwent some form of recon-
struction in the study by Molnar et al. [11].
Balanced general anesthesia combined with epidural
block was the most frequent choice of anesthesia for
Table 3 Perioperative data
Variable Value (n = 35)
Operating time (min)a 200 (90–460)
Type of anesthesia (n)
General plus regional 31
General alone 3
Regional alone 1
Type of general anesthesia (n)
Intravenous 3
Balanced 31
Type of regional anesthesia (n)
Spinal 4
Epidural block 25
Spinal plus epidural block 3
Intraoperative neuroaxial opioids (n) 32
Intraoperative use of colloids, 0.5/1/1.5 L (n) 12/07/03
Intraoperative crystalloid volume (mL)a 3500 (1000–8500)
Intraoperative albumin infusion (n) 6
Intraoperative transfusion (n) 20
Intraoperative red blood cells (units)a 2 (1–6)
Intraoperative use of other blood products (n)
Fresh frozen plasma 3
Cryoprecipitate 1
Platelets 0
Extubation in the operating room (n) 33
aMedian and range
Table 4 Postoperative data
Variable Value
Postoperative transfusion (n) 17
Severe acute pain after the procedure (VAS > 7) (n) 11
Postoperative complications
Acute renal failure (n) 1
Neurological disordersa (n) 2
Arrhythmias (n) 1
Chronic pain 3 months after surgery (n) 14
Surgical wound complications (n) 9
Time to discharge (days)b 6 (3–27)
VAS visual analog scale
aIschemia delirium and/or disorientation
bMedian and range
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hemipelvectomy in this series, and this finding is similar
to the finding of Molnar et al. [11]. Although some stud-
ies suggested that propofol anesthesia was superior to
volatile agents in cancer patients [16, 17], other studies
do not support this suggestion [18–20]. In a recent re-
view, Heaney et al. [18] stated that there is no conclusive
evidence to indicate that one anesthetic agent is better
than another agent in cancer patients. Therefore, there
is no reason to change the current practice.
We observed that efforts were made to deliver regional
anesthetics in every case, and epidural or spinal local an-
esthetics were delivered in 32 of the 35 patients. Usually,
after the surgical plan was discussed, epidural catheters
were positioned in the lower thoracic or upper lumbar
spine to avoid interference with the surgical field. A pre-
vious study reported that neuroaxial opioids were highly
effective at reducing postoperative pain [2]. However, as
31.4 % of patients developed severe postoperative acute
pain in our study, neuroaxial opioids were not able to
provide adequate postoperative analgesia. Nevertheless,
Weinbroum [21] reported the superiority of epidural
over intravenous patient-controlled analgesia in ortho-
pedic oncologic patients, and its use is recommended.
Chronic pain was an important postoperative com-
plication. A total of 14 patients experienced this com-
plication, and among the 23 patients who underwent
external hemipelvectomy, 11 had persistent pain. Per-
sistent postsurgical pain (pain that lasts for more than
1–2 months after surgery) has been reported to be
present in more than 30 % of patients after proce-
dures, such as amputations, and its recognition is
increasing [22]. Studies have shown that up to 90 %
of patients may experience phantom pain after
hemipelvectomy-associated amputation, and although
the mechanisms of pain after this procedure are not
fully understood, the pain can be debilitating and may
impair rehabilitation and quality of life [22, 23].
Neurotoxic chemotherapy, moderate-to-severe postop-
erative pain, anxiety, younger age (adults), radiation
therapy in the operated area, and preoperative pain
(moderate to severe) for more than 1 month were
previously identified as risk factors for the develop-
ment of chronic postsurgical pain [24, 25], and all or
at least some of these factors may be present in
hemipelvectomy patients.
In this study, 25,7 % of cases developed surgical
wound complications that included infection, fistula, and
dehiscence. Previous studies by Higinbotham et al. [26]
and Apffelstaedt et al. [27, 28] reported wound compli-
cation incidences of 75 and 47 %, respectively. Beck et
al. [22] reported a wound complication incidence of only
4 %. Our findings are somewhat similar to the findings
of these previous studies.
The median postoperative length of hospital stay was
6 days (range, 3–27 days), and there was no difference
between patients who underwent external hemipelvect-
omy and those who underwent internal hemipelvectomy.
The length of time was shorter than in the study by Beck
et al. [22] (14 days for internal and 20 for external hemi-
pelvectomy) and by Molnar et al. [11] (14 days). Team
efforts, institutional experience, and a low incidence of
clinical complications may explain the earlier hospital
discharge in our study.
This study did not focus on rehabilitation data. As a
routine, all efforts were made to deliver early rehabilita-
tion. Main goals were to sit in the first postoperative day
and stand up in the fourth and, at discharge, patients
were scheduled for ambulatory physiotherapy. Ampu-
tated patients received focus on wound edges care and
preparation for prostheses. Internal hemipelvectomy pa-
tients received ambulatory ambulation training, corporal
balance, and other mobility training such as gait aid.
A retrospective case series approach is useful to study
rare diseases and infrequent procedures. However, several
limitations are associated with this approach. This study
was performed at a single center, and this might have re-
sulted in bias. The large number of patients with advanced
disease stage, especially in the soft tissue sarcoma group,
Table 5 Perioperative data (external hemipelvectomy vs. internal hemipelvectomy)
Internal (without reconstruction) External
Variable n Median Range n Median Range P value
Age (years) 12 40 32–46 23 45 29–55 0.39
Weight (kg) 12 75 64–81 23 63 52–83 0.15
Operation duration (min) 12 240 140–284 23 195 160–225 0.53
Intraoperative RBC transfusion (units) 6 4 1.8–6.0 14 2 2.0–3.0 0.13
Intraoperative crystalloid infusion (mL) 12 3750 2825–5000 23 3000 2500–4000 0.29
Postoperative RBC transfusion (units) 3 3 1.0–4.0 21 2 1.0–2.0 0.38
Total RBC transfusion (units) 7 4 1.0–8.0 14 3 2.0–4.0 0.4
Hospital stay after surgery (days) 12 6 5.0–7.0 23 6 4.0–8.0 0.68
RBC red blood cell
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may have contributed to low sample survival as well as
worse outcome in external hemipelvectomy. Reports from
different centers are important to contribute to increased
knowledge about the outcomes of such aggressive and
potentially critical procedures.
Conclusions
In conclusion, hemipelvectomy is an aggressive proced-
ure and despite advances in surgical and perioperative
management, the overall mean survival time after sur-
gery may be considered low (32.8 months in the present
series). Advanced disease stage might be independently
associated with reduced survival and although consider-
ably smaller amounts of fluids and transfusions were
administered and time to discharge was shorter, acute
and chronic pain as well as wound complications are
still important challenges in hemipelvectomy.
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